杨益波 余保平

    [摘要] 肝细胞癌(HCC)是常见的恶性肿瘤之一，具有较高的致死率，HCC的早期有效诊断至关重要。微小RNA(miRNA)参与肝癌细胞增殖、分化、迁移、新生血管生成、细胞凋亡等活动过程，有望成为协助肝癌的诊断、治疗及预后判断的新生生物标志物。本文主要将血清或血浆的miRNA在肝癌临床应用中的研究进展作一综述，旨在为肝癌的临床诊断、治疗以及评估肝癌的预后提供新思路。

    [关键词] 微小RNA;肝细胞癌;早期检测;治疗;预后

    [中图分类号] R735.7 ? ? ? ? ?[文献标识码] A ? ? ? ? ?[文章编号] 1673-7210(2020)06(a)-0045-04

    [Abstract] Hepatocellular carcinoma (HCC) was one of the common malignant tumors with a high mortality rate. Early and effective diagnosis of HCC was essential. MicroRNA (miRNA) was involved in the proliferation， differentiation， migration， neovascularization， apoptosis and other activities of liver cancer cells， which was expected to become new biomarkers to assist in the diagnosis， treatment and prognosis of liver cancer. This article mainly reviews the research progress of serum or plasma miRNA in the clinical application of liver cancer， and aimed to provide new ideas for the clinical diagnosis， treatment and evaluation of liver cancer prognosis.

    [Key words] MicroRNA; Hepatocellular carcinoma; Early detection; Treatment; Prognosis

    肝細胞癌(HCC)是第五大最常见的恶性肿瘤和第三大致死性癌症[1] ......